In 2017, it is two hundred years since James Parkinson provided the first complete clinical
description of the disease named after him, fifty years since the introduction of high-dose D …

Presynaptic nerve terminals release neurotransmitters by synaptic vesicle exocytosis.
Membrane fusion mediating synaptic exocytosis and other intracellular membrane traffic is …

Human genetics has indicated a causal role for the protein α-synuclein in the pathogenesis
of familial Parkinson's disease (PD), and the aggregation of synuclein in essentially all …

Presynaptic nerve terminals release neurotransmitters repeatedly, often at high frequency,
and in relative isolation from neuronal cell bodies. Repeated release requires cycles of …

Considerable evidence supports the release of pathogenic aggregates of the neuronal
protein α-Synuclein (αSyn) into the extracellular space. While this release is proposed to …

The protein α-synuclein accumulates in the brain of patients with sporadic Parkinson's
disease (PD), and increased gene dosage causes a severe, dominantly inherited form of …

Summary α-synuclein and cysteine-string protein-α (CSPα) are abundant synaptic vesicle
proteins independently linked to neurodegeneration. Dominantly inherited mutations in α …

Human cancer cell lines are an integral part of drug discovery practices. However, modeling
the complexity of cancer utilizing these cell lines on standard plastic substrata, does not …

Neurotransmitter release is governed by proteins that have homo-logs in most types of
intracellular membrane fusion, including the Sec1/Munc18 protein Munc18-1 and the …

It is now known that proteins associated with neurodegenerative disease can spread
throughout the brain in a prionlike manner. However, the mechanisms regulating the trans …